

## United States Patent and Trademark Office

UNITED STADES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/764,330	01/23/2004	Michael P. Cooke	P1097US10	5772	
29490	7590 08/23/2006		EXAMINER		
GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION			JUEDES,	JUEDES, AMY E	
	S RESEARCH FOUNDATION N JAY HOPKINS DRIVE, SUITE E225		ART UNIT	PAPER NUMBER	
SAN DIEGO,	CA 92121-1127		1644		
			DATE MAILED: 08/23/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/764,330	COOKE ET AL.				
		Examiner	Art Unit				
		Amy E. Juedes, Ph.D.	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)[X]	Responsive to communication(s) filed on 2/10/	06.					
—	This action is <b>FINAL</b> . 2b) This action is non-final.						
<i>,</i> —	, ————————————————————————————————————						
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)🛛	4)⊠ Claim(s) <u>1-27</u> is/are pending in the application.						
. 4	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) 🔲 🖟	Claim(s) is/are objected to.						
8)🛛 (	8) Claim(s) <u>1-27</u> are subject to restriction and/or election requirement.						
Application	on Papers						
9)☐ The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  4) Interview Summary (PTO-413) Paper No(s)/Mail Date.  5) Notice of Informal Patent Application (PTO-152)							
Paper No(s)/Mail Date 6) Uther:							

Application/Control Number: 10/764,330

Art Unit: 1644

## DETAILED ACTION

Page 2

1. The examiner of this application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Amy E. Juedes, Group Art Unit 1644, Technology Center 1600.

- 1. Applicant's election of group I, drawn to a method of identifying an agent, in the reply filed 2/10/06 is acknowledged. However, upon reconsideration, the restriction requirement issued on 1/11/06 is withdrawn. The following is a new requirement for restriction.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
  - I. Claims 1-16, drawn to a method for identifying an agent that modulates T lymphocyte development or function, comprising assaying a cellular activity of an inositol 1,4,5-triphosphate 3-kinase (IPK3) in the presence of a test compound, classified in Class 424, subclass 157.1.
  - II. Claims 17-22, drawn to a method of suppressing an undesired T lymphocyte response in a subject, comprising administering to the subject an agent that inhibits a cellular activity of an IP3K, classified in Class 424, subclass 9.1.
  - III. Claims 23-27, drawn to a method for modulating T lymphocyte differentiation in a subject, comprising screening test compounds and administering to the subject a pharmaceutical composition comprising the modulating agent, classified in Class 424, subclass 9.2.
- 3. Groups I-III are unrelated methods. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects. (MPEP'806.04, MPEP'808.01). In the instant case the different inventions are drawn to methods comprising different method steps, different reagents, resulting in different end points. For example, in group I an agent that modulates T lymphocyte development or function is identified vs. group II where undesired T lymphocyte response in a subject is suppressed vs.

Application/Control Number: 10/764,330

Art Unit: 1644

group III where T lymphocyte differentiation in a subject is modulated.

Page 3

4. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art because of their recognized divergent subject matter. Further, a different field of search would be required based upon the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper. Further, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention.

## Species Election

- 5. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.
- 6. If groups I is elected, applicant is required to:
- A) elect a specific IP3KB, such as one of those listed in claims 6-7.
- B) indicate which claims read on the elected species, including any claims subsequently added.

These are distinct species because their physiochemical properties differ, due to their unique sequences.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

11. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/764,330

Art Unit: 1644

7. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Amy E. Juedes whose telephone number is 571-272-4471. The examiner can normally be reached on 8am 5pm from Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Amy E. Juedes, Ph.D. Patent Examiner Technology Center 1600 August 15, 2006

G.R. EWOLDT, PH.D. PRIMARY EXAMINER